When and to whom should the IMBG be performed?

The IMBG is being currently clinically tested in patients with early disease (2010 classification criteria for RA from American College of Rheumatology (ACR). The objective is to test if IMBG can be used to identify the patients´ sensitivity/resistance profile to first line treatments for RA before treatment is begun and to advise over the treatment adequacy after 3/6 months of follow-up when remission is not achieved. One important goal is to demonstrate if IMBG can be used to identify and monitor patients with a higher probability of resistance to methotrexate to allow physicians to take a quicker treatment change orientation to achieve remission.

It is also being tested in patients with a chronic AR when they are treated with the IMS tested, to facilitate therapeutic decisions.